Modality
Peptide
MOA
KRASG12Ci
Target
WRN
Pathway
Neuroinflam
Pompe
Development Pipeline
Preclinical
~Nov 2016
→ ~Feb 2018
Phase 1
~May 2018
→ ~Aug 2019
Phase 2
~Nov 2019
→ ~Feb 2021
Phase 3
~May 2021
→ ~Aug 2022
NDA/BLA
Nov 2022
NDA/BLACurrent
NCT03871867
505 pts·Pompe
2022-11→TBD·Completed
505 total pts1 indication
Approved
CompletedCurrentUpcoming
Trial Timeline
NDA/BLA
Complet…
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03871867 | NDA/BLA | Pompe | Completed | 505 | PANSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Lisolucimab | Novartis | Approved | CD20 | |
| Gozelemzoparlimab | Merck & Co | Phase 2 | FXIa | |
| MRK-3745 | Merck & Co | Phase 2 | WRN | |
| Zorisotorasib | AstraZeneca | Phase 1 | WRN | |
| AZN-8478 | AstraZeneca | NDA/BLA | SHP2 | |
| BMY-3371 | Bristol-Myers Squibb | Phase 3 | WRN | |
| Pexazasiran | Sanofi | Preclinical | FXIa | |
| Terasacituzumab | Novo Nordisk | NDA/BLA | IL-23 | |
| Lisorapivir | Takeda | Preclinical | WRN | |
| Nirafutibatinib | Bayer | Phase 2 | WRN |